Shenzhen Hepalink Pharmaceutical inked a stock purchase agreement for $337.5 million to acquire Scientific Protein Laboratories (SPL), which makes and supplies active pharmaceutical ingredients (APIs). Hepalink officials say the deal will expand its presence as one of the world’s leading heparin suppliers, while providing the combined company with greater product development and growth opportunities in new markets for its full line of APIs, including pancreatic enzyme and heparin products.

The acquisition allows for greater investment in R&D and new products and processes, and will form a stronger company with enhanced cutting-edge R&D capabilities in the global heparin API sector, according to Li Li, chairman and CEO of Hepalink.

“We are excited about this transaction and what it means for Scientific Protein Laboratories,” added Robert Mills, CEO of SPL. “This will expand our ability to develop and grow both our domestic and international businesses and to continue to conduct cutting-edge research on new products. We do not anticipate any changes in how we currently do business. We will become part of a very successful company that shares our commitment to safety and quality.”

When the transaction is completed, SPL’s management will remain in place, as will its 204 employees in the United States, explained Hepalink officials. SPL’s principal facility is in Waunakee, WI.

Previous articleHuge Gene Study Boosts New Drug Hopes for Rheumatoid Arthritis
Next articleFlip On, Flip Off: Tet/DNA Epigenetic Mechanism Uncovered